Today was an explosive day in the biotech-verse as CymaBay Therapeutics Inc (NASDAQ:CBAY) shot up on back of H.C.
In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) with a $14 price target, …
